Teicoplanin inhibits Ebola pseudovirus infection in cell culture

Antiviral Res. 2016 Jan:125:1-7. doi: 10.1016/j.antiviral.2015.11.003. Epub 2015 Nov 14.

Abstract

There is currently no approved antiviral therapy for treatment of Ebola virus disease. To discover readily available approved drugs that can be rapidly repurposed for treatment of Ebola virus infections, we screened 1280 FDA-approved drugs and identified glycopeptide antibiotic teicoplanin inhibiting Ebola pseudovirus infection by blocking virus entry in the low micromolar range. Teicoplanin could be evaluated further and incorporated into ongoing clinical studies.

Keywords: Antiviral drug discovery; Ebola; High-throughput screening; Pseudovirus; Teicoplanin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Chlorocebus aethiops
  • Drug Evaluation, Preclinical / methods
  • Ebolavirus / drug effects*
  • Ebolavirus / physiology
  • Hemorrhagic Fever, Ebola / drug therapy
  • Hemorrhagic Fever, Ebola / prevention & control
  • Hemorrhagic Fever, Ebola / virology
  • High-Throughput Screening Assays / methods
  • Humans
  • Teicoplanin / pharmacology*
  • Vero Cells
  • Virus Internalization / drug effects
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Teicoplanin